دورية أكاديمية

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy

التفاصيل البيبلوغرافية
العنوان: Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism That Increases Risk of Docetaxel-Induced Neuropathy
المؤلفون: Hertz, Daniel L., Owzar, Kouros, Lessans, Sherrie, Wing, Claudia, Jiang, Chen, Kelly, William Kevin, Patel, Jai, Halabi, Susan, Furukawa, Yoichi, Wheeler, Heather E., Sibley, Alexander B., Lassiter, Cameron, Weisman, Lois, Watson, Dorothy, Krens, Stefanie D., Mulkey, Flora, Renn, Cynthia L., Small, Eric J., Febbo, Phillip G., Shterev, Ivo, Kroetz, Deanna L., Friedman, Paula N., Mahoney, John F., Carducci, Michael A., Kelley, Michael J., Nakamura, Yusuke, Kubo, Michiaki, Dorsey, Susan G., Dolan, M. Eileen, Morris, Michael J., McLeod, Howard L.
المصدر: Biology: Faculty Publications and Other Works
بيانات النشر: Loyola eCommons
سنة النشر: 2016
المجموعة: Loyola University Chicago: Loyola eCommons
مصطلحات موضوعية: docetaxel, paclitaxel, pharmacogenetics, genome-wide association study, heritability, single nucleotide polymorphism, chemotherapy-induced peripheral neuropathy, VAC14, peripheral neuronal cell model, animal model, Biology
الوصف: Purpose Discovery of single nucleotide polymorphisms (SNPs) that predict a patient's risk of docetaxel-induced neuropathy would enable treatment individualization to maximize efficacy and avoid unnecessary toxicity. The objectives of this analysis were to discover SNPs associated with docetaxel-induced neuropathy and mechanistically validate these associations in preclinical models of drug-induced neuropathy. Experimental Design A genome-wide association study was conducted in metastatic castrate-resistant prostate cancer patients treated with docetaxel, prednisone and randomized to bevacizumab or placebo on CALGB 90401. SNPs were genotyped on the Illumina HumanHap610-Quad platform followed by rigorous quality control. The inference was conducted on the cumulative dose at occurrence of grade 3+ sensory neuropathy using a cause-specific hazard model that accounted for early treatment discontinuation. Genes with SNPs significantly associated with neuropathy were knocked down in cellular and mouse models of drug-induced neuropathy. Results 498,081 SNPs were analyzed in 623 Caucasian patients, 50 (8%) of whom experienced grade 3+ neuropathy. The 1000 SNPs most associated with neuropathy clustered in relevant pathways including neuropathic pain and axonal guidance. A SNP in VAC14 (rs875858) surpassed genome-wide significance (p=2.12×10-8 adjusted p=5.88×10-7). siRNA knockdown of VAC14 in stem cell derived peripheral neuronal cells increased docetaxel sensitivity as measured by decreased neurite processes (p=0.0015) and branches (p<0.0001). Prior to docetaxel treatment VAC14 heterozygous mice had greater nociceptive sensitivity than wild-type litter mate controls (p=0.001). Conclusions VAC14 should be prioritized for further validation of its potential role as a predictor of docetaxel-induced neuropathy and biomarker for treatment individualization.
نوع الوثيقة: text
وصف الملف: application/pdf
اللغة: unknown
العلاقة: https://ecommons.luc.edu/biology_facpubs/101Test; https://ecommons.luc.edu/context/biology_facpubs/article/1106/viewcontent/Wheeler2.pdfTest
DOI: 10.1158/1078-0432.CCR-15-2823
الإتاحة: https://doi.org/10.1158/1078-0432.CCR-15-2823Test
https://ecommons.luc.edu/biology_facpubs/101Test
https://ecommons.luc.edu/context/biology_facpubs/article/1106/viewcontent/Wheeler2.pdfTest
حقوق: http://creativecommons.org/licenses/by-nc-nd/3.0Test/
رقم الانضمام: edsbas.2F0A064
قاعدة البيانات: BASE